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Abstract
Ischemic stroke is a major cause of mortality and morbidity globally. Among the ischemic
stroke subtypes, cardioembolic stroke is with poor functional outcome (Modified Rankin
score 2). Early diagnosis of cardioembolic stroke will prove beneficial. This study exam-
ined the microRNAs targeting cluster of differentiation 46 (CD46), a potential biomarker for
cardioembolic stroke. CD46 mRNA level was shown to be differentially expressed (p <
0.001) between cardioembolic stroke (median = 1.32) and non-cardioembolic stroke sub-
types (large artery stroke median = 5.05; small vessel stroke median = 6.45). Bioinformatic
search showed that miR-19a, -20a, -185 and -374b were found to target CD46 mRNA and
further verified by luciferase reporter assay. The levels of miRNAs targeting CD46 were
significantly reduced (p < 0.05) in non-cardioembolic stroke patients (large artery stroke
median: miR-19a = 0.63, miR-20a = 0.42, miR-185 = 0.32, miR-374b = 0.27; small artery
stroke median: miR-19a = 0.07, miR-20a = 0.06, miR-185 = 0.07, miR-374b = 0.05) as
compared to cardioembolic stroke patients (median: miR-19a = 2.69, miR-20a = 1.36,
miR-185 = 1.05, miR-374b = 1.23). ROC curve showed that the miRNAs could distinguish
cardioembolic stroke from non-cardioembolic stroke with better AUC value as compared
to CD46. Endogenous expression of CD46 in Human Umbilical Vein Endothelial Cells
(HUVECs) were found to be regulated by miR-19a and miR-20a. Thus implicating that
miR-19a and -20a may play a role in pathogenesis of cardioembolic stroke, possibly via
the endothelial cells.
Introduction
Ischemic stroke is one of the leading causes of death and disabilities worldwide. It accounts
for 80% of all reported stroke cases [1–3]. According to Trial of Org 10172 in Acute Stroke
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Treatment (TOAST) classification [4], among the different ischemic stroke subtypes, cardi-
oembolic stroke, a type of ischemic stroke characterized by the blood clot originating from a
cardioembolic source, is associated with poor functional outcome (based on Modified Rankin
score) in patients [5]. However, the current challenge for cardioembolic stroke diagnosis is the
lack of an accurate diagnosis to segregate cardioembolic stroke cases from large artery stroke
cases (which is another common ischemic stroke subtype). Hence, identification of specific
biomarkers for cardioembolic stroke will prove beneficial.
Previous reports had highlighted a group of mRNAs which can potentially classify ischemic
stroke patients into their various stroke subtypes [6], [7]. Among these mRNAs, there was an
inhibitor of complement cascade, cluster of differentiation 46 (CD46) [8], which could distin-
guish cardioembolic stroke from non-cardioembolic stroke subtype [6], [7]. Components of
complement cascade that had been found to be increased in ischemic stroke patients, have also
been observed to be associated with stroke outcome [9–11]. This denotes that complement cas-
cade is deregulated during ischemic stroke and hence can be a potential biomarker for ische-
mic stroke. Thus, it would be beneficial to investigate how the differential expression of CD46
contributes to the pathogenesis of the different stroke subtypes.
As the expression pattern of microRNAs (miRNAs) present in blood changes in response
to different disease states, we studied them to obtain information on the molecular mechanism
of cardioembolic stroke pathogenesis involving CD46. miRNAs are a class of short (18–22
nucleotides), endogenously expressed, non-coding RNAs that act as riboregulators of gene
expression [12], [13]. Typically, miRNAs down-regulate gene expression of target mRNA
through the process of RNA interference (RNAi) [13]. A single miRNA can target multiple
genes and it can also have an overall effect on certain pathways. Hence, looking into miRNAs
targeting CD46 can potentially uncover the differential pathway regulation between cardioem-
bolic and non-cardioembolic stroke. Thus, this study was aimed to identify the miRNAs tar-
geting CD46 as they may serve as potential biomarkers and to uncover the mechanism behind
differential expression of CD46 between cardioembolic and non-cardioembolic stroke.
Materials and methods
Patient recruitment
This study was approved by the Medical Ethics Committee of the University Malaya Medical
Centre (UMMC), Kuala Lumpur, Malaysia (Ref. No: 607.20) and the Institutional Review
Board (IRB) of the National University of Singapore (NUS; NUS-IRB Ref Code: 08–381;
Approval: NUS-676), and was carried out in accordance with the Declaration of Helsinki
(2008). Written informed consent was obtained from patients and was carried out with the
approval of the ethics committee and IRB. The patients were recruited from University Malaya
Medical Centre (UMMC), Kuala Lumpur, Malaysia. The patients were admitted into UMMC
via the Neurology service and Accident and Emergency (A&E) department. Ischemic stroke in
patients were diagnosed through either magnetic resonance imaging (MRI) or computed
tomography (CT) scan. Blood samples were collected from patients within 24 hours following
admission. Peripheral blood was collected by venepuncture into BD Vacutainer with no addi-
tive (BD, Franklin Lakes, NJ, US; Cat# 366703) and was immediately aliquoted into Eppendorf
tubes containing RNA later (Ambion, Life Technology, Carlsbad, CA, US) according to manu-
facturer’s protocol. These samples were stored at -80˚C until required.
39 patients and 18 healthy controls were recruited for this study. Patients were classified
according to the Trial of Org 10172 in Acute Stroke Treatment (TOAST) classification [4]
(Table 1). The outcomes of the patients were assessed using the modified Rankin scale (mRS)
[5] and dichotomized into good (mRS < 2) and poor outcome (mRS 2; Table 1).
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Transfection of miRNAs in HUVECs
Human umbilical vein endothelial cells (HUVEC, CRL-1730; ATCC, US) were cultured using
Dulbecco’s Modified Eagle Medium (DMEM; Gibco, Carlsbad, CA, US) supplemented with
10% fetal bovine serum (Gibco, Carlsbad, CA, US) and 1% penicillin-streptomycin (Gibco,
Carlsbad, CA, US) and maintained at 37˚C in 5% carbon dioxide. HUVECs were seeded at
density of 3 X 104 cells in each well of 24 well plates. Human anti-miRNAs and miRNA mimics
were transfected at final concentration of 30 nM in 50 μl of Opti-MEM (Gibco, Carlsbad, CA,
US) complexed with 1 μl of NeoFx in 50 μl of Opti-MEM (Gibco, Carlsbad, CA, US) per well.
Cells were cultured at 37˚C in 5% carbon dioxide for 48 hours.
RNA isolation
Total RNAs (+miRNAs) were isolated from blood using Ambion Ribopure blood extraction
kit (Ambion, Life Technology, Carlsbad, CA, US) according to manufacturer’s protocol. Total
RNAs (including miRNAs) were isolated from cells using TRIzol reagent (Invitrogen, Carls-
bad, CA, US) according to manufacturer’s protocol. The concentration and integrity of total
RNAs were determined by the Nano-Drop ND-1000 Spectrophotometry (NanoDrop Tech,
Wilmington, DE, US) and denaturing agarose gel electrophoresis.
Cloning of CD46 3’UTR fragment
Gene specific primers were used to amplify the region of CD46 3’UTR containing the seed
regions of the miRNAs (forwardprimer,5’- GACAGCCATAACAGGAGTGC– 3’;
reverseprimer,5’–ACTTCCAGAGAAAACTGGTC– 3’). The PCR product was cloned
into pMIR-REPORT Luciferase vector (Promega, Madison, WI, US) at the SpeI and HindIII
multi-cloning sites.
Luciferase assay
Luciferase assay was performed according to Sepramaniam et al [14]. HeLa cells (CCL-2;
ATCC, USA) were cultured using Dulbecco’s Modified Eagle Medium (DMEM; Gibco, Carls-
bad, CA, US) supplemented with 10% fetal bovine serum (Gibco, Carlsbad, CA, US) and 1%
penicillin-streptomycin (Gibco, Carlsbad, CA, US) and maintained at 37˚C in 5% carbon
Table 1. Patients’ demography.
Control (n = 18) CE stroke (n = 13) Non-CE stroke (n = 26) p-value (CE vs Non-CE)
Age (Mean ± SD) 42.87 ± 12.42 67.50 ± 16.13 62.84 ± 11.61 0.19
Female, n (%) 6(33.33%) 5 (41.67%) 10 (38.46%) 0.27
Dyslipidaemia, n (%) NA 9 (75.00%) 19 (73.08%) 0.30
Diabetes mellitus, n (%) NA 5 (41.67%) 14 (53.85%) 0.21
Hypertension, n (%) NA 5 (41.67%) 20 (76.92%) 0.03
Ischemic heart disease, n (%) NA 4 (33.33%) 6 (23.08%) 0.24
Atrial fibrillation, n (%) NA 10 (83.33%) 0 (0.00%) <0.001
Previous stroke, n (%) NA 3 (25.00%) 3 (11.54%) 0.20
Smoking, n (%) NA 0 (0.00%) 5 (19.23%) 0.13
Alcohol, n (%) NA 0 (0.00%) 1 (3.84%) 0.68
Modified Rankin Scale < 2, n (%) NA 1 (8.33%) 6 (23.07%) 0.21
The patients were classified according to cardioembolic stroke and non-cardioembolic stroke (large artery stroke and small vessel stroke). The various
parameters were tested using Mann-Whitney U test. CE: cardioembolic. Non-CE: Non-cardioembolic.
doi:10.1371/journal.pone.0172131.t001
MicroRNAs regulating CD46 in cardioembolic and non-cardioembolic stroke
PLOS ONE | DOI:10.1371/journal.pone.0172131 February 15, 2017 3 / 16
dioxide. Cells were transfected with 50nM anti-miRNAs or miRNA mimics for 3 hours fol-
lowed by 100 ng/well pMIR-REPORT Luciferase vector for 3 hours as previously shown by
Sepramaniam et al [14] and Kaur et al [15]. The cells were lysed 48 h later for measurement of
luciferase activity. Dual luciferase assay (Promega, Madison, WI, US) was used to quantitate
the effects of anti- or pre-miRNA interaction with CD46 3’UTR. The assay was performed
according to the manufacturer’s protocol. In all experiments, transfection efficiencies were
normalized to those of cells co-transfected with the Renilla luciferase expressing vector
(pRL-CMV; Promega, Madison, WI, US) at 10 ng/well.
Reverse transcription and real-time qualitative polymerase chain
reaction (qPCR)
Reverse transcription followed by real-time qualitative PCR were carried out according to
Kaur et al. [15] For gene quantification, reverse transcription was performed using TaqMan
Reverse Transcription kit (Applied Biosystems, Foster City, CA, US) according to manufactur-
er’s protocol. Quantification of CD46 mRNA was performed using SYBR Green assay (Applied
Biosystems, Foster City, CA, US) and GAPDH was used as an endogenous control [15] for
normalization (CD46 forwardprimer,5’-GGTGTTGCTGCTGTACTCCTTCT-3’;
CD46 reverseprimer,5’-CCAATGAGCTCCATAGCTTCAA-3’;GAPDH forward
primer,5’-AACAGCGACACCCATCCTC-3’;GAPDH reverseprimer,5’-CATACC
AGGAAATGAGCTTGACAA-3’)
For microRNA quantification, reverse transcription was performed using TaqMan Micro-
RNA Reverse Transcription kit (Applied Biosystems, Foster City, CA, US) with microRNA-
specific stem-loop primers. The microRNA expression was normalized to endogenous control
GAPDH [15]. Subsequently, miRNA quantitation was performed using TaqMan chemistry.
All reactions were conducted on Applied Biosystems 7900HT Fast Real-time PCR system
(Applied Biosystems, Foster City, CA, US).
Protein gel and Western blot analysis
Protein was obtained from the phenol phase of the RNA extraction reaction (Invitrogen, Carls-
bad, CA, US) and quantified using Bio-Rad protein assay (Bio-Rad, Hercules, CA, US). 40 μg
of total protein was resolved using Bolt 4–12% Bis-Tris plus gel (Novex, Life Technologies,
Grand Island, NY, US) and transferred using the iBlot gel transfer system (Novex, Life Tech-
nologies, Grand Island, NY, US). The membranes were probed using the iBind Flex Western
Device (Thermo Fisher Scientific, Waltham, MA, US) according to manufacturer’s protocol,
using primary antibodies for CD46 (1:1000; Abcam, Cambridge, UK; Cat# ab789), primary
antibodies for β-Actin (1:5000; Bio-Rad, Hercules, CA, USA; Cat# MCA5775GA) and second-
ary antibodies (1:5000; horseradish peroxidase-conjugated goat anti-mouse; Bio-Rad, Hercu-
les, CA, USA; Cat# 1721011). The proteins on the membranes were visualized via enhanced
chemiluminescence (SuperSignal West; Thermo Fisher Scientific, Waltham, MA, USA) and
exposed to hyperfilm (Amersham hyperfilm, GE healthcare lifescience, Little Chalfont, UK).
The labelling intensities of the bands were quantitated using ImageJ software (National Insti-
tutes of Health, Bethesda, MD, US) [16].
Immunocytochemistry
Immunocytochemistry was performed on HUVECs treated with anti-miRNAs and miRNA
mimics. The cells were fixed with 4% formaldehyde in phosphate-buffered saline for 20 min,
permeabilized with 0.1% Triton X-100 in PBS for 30 min, and blocked with 5% FBS in PBST
for 30 min. CD46 was probed using primary antibodies for CD46 (1:100; Abcam, Cambridge,
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UK; Cat# ab789) and Texas Red conjugated secondary antibodies (1:200; Abcam, Cambridge,
UK; Cat# ab7066). 0.1 μg/mL Hoechst 33342 (Biotium, Foster City, CA, USA) was used for
visualising the nucleus. The images were viewed and analysed using LSM710 confocal imaging
software (Carl Zeiss AG, Oberkochen, Germany).
In silico prediction
Bioinformatics prediction of miRNAs targeting CD46 was performed using available databases
online: Targetscan version 6.2 (www.targetscan.org) [17–20], miRanda August 2010 release
(www.microRNA.org) [21–24], microcosm version 5 (www.ebi.ac.uk/enright-srv/microcosm/
htdocs/targets/v5/) [24–26], DIANA microT version 3 (http://diana.cslab.ece.ntua.gr/microT/)
[27], [28], miRDB version 4 (mirdb.org/) [29], [30], miRWalk March 2011 update (www.ebi.
ac.uk/enright-srv/microcosm/htdocs/targets/v5/) [31], PITA 2007 release (genie.weizmann.ac.
il/pubs/mir07/mir07_prediction.html) [32], RepTar version 1.2 (reptar.ekmd.huji.ac.il/) [33]
and StarBase version 2 (starbase.sysu.edu.cn/) [34], [35]. The binding energy of between the
3’UTR and the miRNA was determined using available software RNA22 version 2 (https://cm.
jefferson.edu/rna22/Interactive/) [36].
In silico analysis
Bioinformatics prediction of miRNAs targeting CD46 was performed using available databases
online. Pathway analysis was conducted using DIANA miRPath version 2 (http://diana.imis.
athena-innovation.gr/DianaTools/index.php?r=mirpath/index) [37]. Gene ontology (GO)
analysis was performed using GeneCodis version 3 (http://genecodis.cnb.csic.es/) [38–40],
using the list of predicted genes from miRPath.
Statistical and data analysis
Statistical significance was set at p-value<0.05. All analyses were performed using Microsoft
Excel 2010 and SPSS version 16. MiRNA expression levels were expressed as fold change rela-
tive to the respective control samples. Hierarchical clustering was plotted using TIGR Multiple
Experiment Viewer (TMeV; http://www.tm4.org/mev/) [41]
Results
CD46 mRNA expression in various stroke subtypes
CD46 mRNA measurements were quantitated in ischemic stroke patients (Patients’ demogra-
phy in Table 1). CD46 mRNA levels were found to be significantly higher (p-value< 0.001) in
large artery (median = 5.05; interquartile range = 2.54–6.46) and small vessel stroke patients
(median = 6.45; interquartile range = 3.87–9.90) as compared with cardioembolic stroke
patients (median = 1.32; interquartile range = 0.86–1.58; Fig 1A). This observation is consis-
tent with previous findings that CD46 mRNA was differentially expressed between cardioem-
bolic stroke and non-cardioembolic stroke (large artery and small vessel stroke) [6], [7]. Thus,
it is important to identify the miRNAs that target CD46 mRNA in order to demonstrate the
potential of using miRNAs as biomarkers to distinguish cardioembolic stroke from non-cardi-
oembolic stroke.
Identification of miRNAs targeting CD46 mRNA
Bioinformatics analysis was performed to identify miRNAs targeting CD46 mRNA. A total of
9 miRNA prediction databases that were available online were used [17–36]. A total of 857
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miRNAs (at least in one of the database) have been found to target CD46 3’UTR. This was nar-
rowed down to 157 miRNAs by comparison with our group’s previously published data on
miRNA profiles from ischemic stroke patients [42]. Among them, 12 miRNAs (miR-17, -18a,
-19a, -19b, -20a, -20b, -106b, -181a, -181b, -185, -374b and -421) were predicted by 5 or more
databases to target CD46 mRNA. Of these, miR-19a, -20a, -185 and -374b were finally selected
as they had the lowest binding energies to the CD46 3’UTR (Fig 1B).
miR-19a, -20a, -185 and -374b targets CD46 mRNA
In order to validate that miR-19a, -20a, -185 and -374b target CD46 mRNA, luciferase reporter
assay was performed. The 3’ untranslated region (3’UTR) of CD46 was sub-cloned into the
pMIR-REPORT™ plasmid and used for co-transfection with respective anti-miRNA or
miRNA mimics in HeLa cells. The success of transfection was verified by measuring the level
of respective miRNAs in the transfected cells (Fig 1C). Cells transfected with anti-miRNAs
exhibited an increase in relative luciferase activity, while cells transfected with miRNA mimics
showed a reduction in relative luciferase activity (Fig 1D). The results demonstrated that CD46
mRNA is a bona fide target of miR-19a, -20a, -185 and -374b.
Fig 1. CD46 mRNA level in cardioembolic and non-cardioembolic (large artery and small vessel stroke) patients and miRNAs targeting
CD46. A. CD46 mRNA level in patients. Data expressed as relative expression with respect to control samples, with the number of patients and
controls indicated. CE represents cardioembolic stroke. LA represents large artery stroke. SV represents small vessel stroke. Data in A are shown as
relative expression. B. miRNA binding sites and binding energies. Nucleotides in bold denoted the seed region. C. Luciferase assay. D. miRNA levels
in transfected HeLa cells. Data in C and D are shown as mean ± SD. All experiments were performed in n = 3. * denotes significant difference
(p < 0.05) against control (A and C) using Mann-Whitney U test. # denotes significance between cardioembolic and non cardioembolic stroke (A) using
Mann-Whitney U test.
doi:10.1371/journal.pone.0172131.g001
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Differential miRNA expression between cardioembolic stroke and non-
cardioembolic stroke subtypes
Our investigation showed that the expression of miR-19a, -20a, -185 and -374b were signifi-
cantly reduced in large-artery stroke (Median: miR-19a = 0.63, miR-20a = 0.42, miR-
185 = 0.32, miR-374b = 0.27; Interquartile range: miR-19a = 0.47–0.94, miR-20a = 0.26–0.68,
miR-185 = 0.23–0.39, miR-374b = 0.20–0.42; Fig 2A–2D) and small vessel patients (Median:
miR-19a = 0.07, miR-20a = 0.06, miR-185 = 0.07, miR-374b = 0.05; Interquartile range: miR-
19a = 0.03–0.19, miR-20a = 0.03–0.16, miR-185 = 0.02–0.24, miR-374b = 0.01–0.23; Fig 2A–
2D) when compared with the cardioembolic stroke patients (Median: miR-19a = 2.69, miR-
20a = 1.36, miR-185 = 1.05, miR-374b = 1.23; Interquartile range: miR-19a = 0.98–2.98, miR-
20a = 1.17–1.80, miR-185 = 0.85–1.30, miR-374b = 1.06–1.53; Fig 2A–2D). This is as expected
based on our observation that the expression of CD46 was higher in the non-cardioembolic
stroke patients, and thus strongly supports our earlier findings that these miRNAs target CD46
mRNA.
Furthermore, using the expression of CD46 and the expression of miRNAs targeting CD46
(miR-19a, -20a, -185 and -374b), a receiver operating characteristic (ROC) curve was obtained
(Fig 2E). The plot shows that the miRNAs were more effective in distinguishing cardioembolic
stroke patients from non-cardioembolic stroke patients and healthy controls (Fig 2E). This
was denoted by the larger area under curve (AUC) value for the miRNAs than CD46 (AUC
value: CD46 = 0.332, miR-19a = 0.918, miR-20a = 0.953, miR-185 = 0.855, miR-374b = 0.851).
Using TMeV [41], the miRNA expression can be used to plot for hierarchical clustering, which
showed segregation of cardioembolic stroke samples from controls and noncardioembolic
stroke samples (Fig 2F). Hence, these miRNAs may prove to be useful biomarkers for cardi-
oembolic stroke diagnosis.
In silico analysis of pathophysiological mechanism of miRNAs targeting
CD46
In order to determine the possible mechanism behind the dysregulation of CD46 and its
respective miRNAs, in silico analysis was performed to decipher the potential pathways and
processes that were affected during the dysregulation. Pathway analysis was performed using
DIANA miRPath version 2 [37]. The results showed that among the top 10 dysregulated path-
ways (based on enrichment score), there were 3 pathways (Wnt signalling pathway, TGF-beta
signalling pathway and Gap junction) associated with endothelial cells (Table 2) [43–45]. Fur-
ther investigation was conducted by focussing at biological processes and gene ontology (GO).
GO analysis was performed on GeneCodis version 3 (Table 2) [38–40]. There were multiple
biological processes associated with endothelial cells from the GO analysis, pointing to endo-
thelial cells as the possible site of action for the dysregulated gene and miRNAs. Hence, further
verification was performed with human umbilical vein endothelial cells (HUVECs) as a model.
miR-19a and -20a regulate CD46 expression in HUVECs
In order to show miRNAs target CD46 mRNA in endothelial cells, HUVECs were transfected
with either anti-miRNA or miRNA mimics. CD46 mRNA and protein were quantitated in
these cells to determine the effect of miRNAs on CD46 endogenously (Fig 3). The success of
transfection was also verified by measuring the level of respective miRNAs in the transfected
cells (Fig 3B). As expected, the transfection of anti-miRNA caused an increase in CD46 mRNA
level (anti-miR-19a = 1.43 ± 0.14, anti-miR-20a = 1.73 ± 0.07, anti-miR-185 = 1.48 ± 0.09,
anti-miR-374b = 1.27 ± 0.10) while the introduction of miRNA mimic reduced the level of
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Fig 2. miRNAs level in cardioembolic and non-cardioembolic (large artery and small vessel stroke)
patients. A. miR-19a. B. miR-20a. C. miR-185. D. miR-374b. * denotes tested to be significantly different
(p < 0.05) from control (A—D) using Mann-Whitney U test. # denotes tested to be statistically significant
between cardioembolic and non cardioembolic stroke. E. Receiver operating characteristic (ROC) curve for
CD46, miR-19a, -20a, -185 and -374b. F. Hierarchical clustering of control and patients according to miRNA
levels. CE represents cardioembolic stroke. LA represents large artery stroke. SV represents small vessel
stroke. Ctrl represents control. Data are shown as relative expression. Red represents up-regulation. Green
represents down-regulation.
doi:10.1371/journal.pone.0172131.g002
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CD46 mRNA (miR-19a mimic = 0.79 ± 0.04, miR-20a mimic = 0.67 ± 0.09, miR-185
mimic = 0.79 ± 0.04, miR-374b mimic = 0.75 ± 0.07; Fig 3A).
However, at the protein level, only miR-19a and -20a were shown to bring about an effect
on CD46 protein level, which was quantified based on intensity of bands in Western blotting
and measured using ImageJ software [16] The anti-miRNA transfected HUVECs had a signifi-
cant increase in CD46 protein expression (anti-miR-19a = 1.44 ± 0.01, anti-miR-
20a = 1.37 ± 0.00, anti-miR-185 = 0.75 ± 0.00, anti-miR-374b = 0.60 ± 0.00; Fig 3C; S1 Fig)
while miRNA mimic transfection brought about a decrease in CD46 protein level (miR-19a
mimic = 0.70 ± 0.00, miR-20a mimic = 0.59 ± 0.01, miR-185 mimic = 1.08 ± 0.00, miR-374b
mimic = 0.87 ± 0.01; Fig 3C; S1 Fig). This was further verified through immunocytochemistry
(Fig 3D). HUVECs transfected with anti-miRNAs (miR-19a and miR-20a) showed an increase
in CD46 protein, denoted by the increase in red fluorescence as compared with control (Fig
3Di), whilst HUVECs transfected with miRNA mimics showed reduced red fluorescence (Fig
3Dii), signifying decrease in CD46 protein. These results demonstrated the relevance of miR-
19a and -20a targeting CD46 in endothelial cells.
Discussion
Cardioembolic stroke is a subtype of ischemic stroke which is well-known for its high mortal-
ity and morbidity rate. Therefore, it is imperative to identify more accurate markers for cardi-
oembolic stroke as it will have implications on the timely selection of appropriate therapy.
Jickling et al [6], [7] demonstrated that CD46 mRNA was among a list of 40 mRNA as
potential markers for distinguishing ischemic stroke subtypes. Among these 40 mRNAs, CD46
seems to have a direct involvement in the pathophysiology of different ischemic stroke sub-
types. This is not surprising as CD46 is part of the complement cascade which regulates inflam-
mation, a crucial pathological process in the pathophysiology of ischemic stroke. In this study,
Table 2. Table of pathways and Gene Ontology (GO) biological processes associated with miR-19a, -20a, -185 and -374b.
KEGG Pathway Enrichment Score GO Biological Process Enrichment Score
Axon guidance 24.08 cell adhesion 22.90
Wnt signaling pathway 23.66 blood coagulation 14.72
Pathways in cancer 23.50 angiogenesis 13.83
p53 signaling pathway 21.19 canonical Wnt receptor signaling pathway 8.99
Ubiquitin mediated proteolysis 20.44 platelet activation 7.46
Transcriptional misregulation in cancer 20.10 wound healing 7.40
TGF-beta signaling pathway 20.08 positive regulation of angiogenesis 5.74
Endocytosis 19.75 Wnt receptor signaling pathway, calcium modulating pathway 5.57
Melanogenesis 18.83 vascular endothelial growth factor receptor signaling pathway 5.44
Gap junction 17.13 negative regulation of canonical Wnt receptor signaling pathway 5.03
GnRH signaling pathway 16.65 Wnt receptor signaling pathway 4.55
Prostate cancer 15.97 Notch signaling pathway 4.51
MAPK signaling pathway 15.18 cell-matrix adhesion 4.35
HTLV-I infection 15.18 negative regulation of cell adhesion 3.95
Salivary secretion 13.52 transforming growth factor beta receptor signaling pathway 3.95
Calcium signaling pathway 13.35 regulation of cell adhesion 3.65
ABC transporters 13.09 positive regulation of endothelial cell migration 3.60
Melanoma 12.52 positive regulation of vasoconstriction 3.60
Regulation of actin cytoskeleton 12.17 positive regulation of endothelial cell proliferation 3.37
ErbB signaling pathway 12.17 blood vessel development 3.17
doi:10.1371/journal.pone.0172131.t002
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Fig 3. Anti-miRNA and miRNA mimic transfection in HUVECs. A. CD46 mRNA expression in transfected HUVECs. B. miRNA
levels in transfected HUVECs. C. Western blot analysis and respective quatification of CD46 protein in transfected HUVECs.–ve:
Negative; 19a: miR-19a; 20a: miR-20a; 185: miR-185; 374b: miR-374b. D. Immunocytochemistry of transfected HUVECs. All
experiments were performed in n = 3. * denoted tested to be significantly different (p < 0.05) from control (A and C) using Mann-
Whitney U test. Data in A and C were shown as mean ± SD, n = 3.
doi:10.1371/journal.pone.0172131.g003
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we have shown that CD46 mRNA level to be significantly up-regulated in non-cardioembolic
stroke while in cardioembolic stroke the CD46 mRNA level appears to be similar to that of the
healthy controls. This observation is in line with the current literature which suggests that ath-
erosclerosis, the underlying pathology of large artery and small vessel stroke, is largely driven
by the process of inflammation [46].
Furthermore, we have identified endothelial cells as a possible location. It is noteworthy to
mention that endothelial cell dysfunction is an important hallmark in atherosclerosis and it
was previously reported that CD46 protein level was found to be up-regulated in atheroscle-
rotic plaque [47], [48]. Hence, the up-regulation of CD46 mRNA found in patients with large
artery and small vessel stroke is entirely in agreement with current evidence, signifying the
crucial role that CD46 plays in the pathogenesis of large artery and small vessel stroke.
In addition, by using in silico prediction and biochemical methodology we have identified
miR-19a, -20a, -185 and -374b to be targeting CD46. We have utilized luciferase assay, a direct
method that is used to prove the binding between miRNA:mRNA pair in various complemen-
tary binding studies [49], [50]. However, when CD46 protein expression were measured, only
miR-19a and miR-20a proved to be useful to significantly modulate CD46 in HUVECs. miR-
19a has been reported to protect endothelial cells from lipopolysaccharide-induced apoptosis,
which is a characteristic of atherosclerosis [51]. The down-regulation of miR-19a detected in
large artery and small vessel stroke implies the increase in lipopolysaccharide-induced apopto-
sis leading to ischemic stroke onset. This demonstrates the potential mechanism of miR-19a
and -20a in endothelial cells during atherosclerosis and even possibly contributing to large
artery and small vessel stroke.
During the pathway analysis, complement cascade was highlighted to be regulated by miR-
19a, -20a, -185 and -374b. The complement cascade also interacts with the coagulation cas-
cade. Coagulation cascade plays an important role in the formation of blood clot, the underly-
ing cause for most ischemic stroke cases. There is a subtle difference in the induction of
coagulation cascade between cardioembolic stroke and non-cardioembolic stroke (large artery
and small vessel strokes), which is emphasized in the different treatments between cardioem-
bolic stroke and non-cardioembolic stroke [52], [53]. Non-cardioembolic strokes are treated
with anti-platelet drugs as the process of blood clotting is most likely induced via the tissue fac-
tor pathway due to tissue damage, such as rupture of the atherosclerotic plaque [52]. On the
other hand, cardioembolic stroke is treated with anti-coagulants, suggesting that the blood
coagulation follows the intrinsic pathway associated with pooling of blood, which corresponds
to the pathogenesis of blood clot in cardioembolic stroke [53]. It is noteworthy to mention that
miR-19a was reported to possibly modulate tissue factor pathway inhibitor (TFPI) which
could signify that the up-regulation of miR-19a in cardioembolic stroke led to a pro-coagula-
tion state in cardioembolic stroke patients [54]. Also, miR-20a was reported in a panel of miR-
NAs that could distinguish etiology of various ischemic stroke subtypes [37]. This lends
further support to the relevance of this miRNAs in the pathogenesis of cardioembolic stroke.
Interestingly, results from the GO analysis showed that there were biological processes
involved in coagulation cascade (blood coagulation and platelet activation). This seems to sug-
gest that the deregulation of the complement cascade, involving CD46 and miRNAs targeting
CD46 (miR-19a, -20a, -185 and -374b) may be potential markers for the differential regulation
of coagulation cascade between cardioembolic stroke and non-cardioembolic stroke. A pre-
liminary in silico prediction was performed to identify potential mRNA targets of miR-19a,
-20a, -185 and -374b within the complement and coagulation cascade. It is noteworthy to men-
tion that these miRNAs target several other genes in the pathways (miR-19a: 9 targets; miR-
20a: 2 targets; miR-185: 6 targets; miR-374b: 5 targets; Table 3). Hence, a further investigation
into miR-19a, -20a, -185 and -374b modulation of complement and coagulation cascade in
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blood cells may provide further understanding of the molecular mechanism behind the differ-
ence in complement and coagulation cascade activities between cardioembolic stroke and
non-cardioembolic stroke.
In the design of this study, GAPDH was used as an endogenous control for normalization
of miRNA expression. The level of GAPDH was found to be consistent throughout all the
experimental conditions. Despite the length of GAPDH mRNA being longer than the length of
miRNA, numerous studies had used GAPDH as endogenous control for normalizing the level
of miRNAs [55–59], which vindicates its role as an endogenous control for miRNA level
normalization.
In brief, we have verified that CD46 mRNA is differentially expressed between cardioem-
bolic stroke and non-cardioembolic stroke subtypes, where it was up-regulated in non-cardi-
oembolic stroke. Furthermore, miR-19, -20a, -185 and -374b have been demonstrated to target
CD46 mRNA and these miRNAs also showed correspondingly inversed expression when com-
pared to the expression of CD46mRNA where the expression of the miRNAs were down-regu-
lated in non-cardioembolic stroke. In addition, endothelial cells in non-cardioembolic stroke
were likely to be affected by this dysregulation. Among the miRNAs, miR-19a and -20a are the
most likely candidates to be involved in up-regulating CD46 through their down-regulation in
endothelial cells. Based on the ROC plot, miRNAs were more accurate in the diagnosis of car-
dioembolic stroke patients where miR-19a and -20a have been found to have stronger AUC
values (miR-19a = 0.918, miR-20a = 0.953). Nonetheless, more data are needed to identify the
threshold range of CD46 mRNA, miR-19, -20a, -185 and -374b for accurate diagnosis in stroke
patients.
Supporting information
S1 Fig. Western blot analysis and respective quantification of CD46 protein in transfected
HUVECs. A. CD46. B. Beta-actin. 1. Anti-miR-374b. 2. Anti-miR-185. 3. Anti-miR-20a. 4.
Anti-miR-19a. 5. Anti-Negative. 6. miR-374b mimic. 7. miR-185 mimic. 8. miR-20a mimic. 9.
miR-19a mimic. 10. Negative mimic.
(TIFF)
Acknowledgments
This work was supported by the research grants from National Research Foundation (NRF):
R-184-002-165-281, National Medical Research Council (NMRC/EDG): R-183-000-230-275,
and the National Medical Research Council (NMRC/IRG: R-183-000-290-213) Singapore; and
the University of Malaya, Kuala Lumpur, Malaysia (UM/HIR: E0067 & E0036).
Table 3. Predicted targets of miR-19a, -20a, -185 and -374b in complement and coagulation cascade.
hsa-miRNA Predicted targets
miR-19a AT3, CD46, CD55, F5, F13, PAI-1, TF, TFPI and PLAU
miR-20a CD46 and PAI-1
miR-185 CD46, F7, F8, F11, F13 and PLAT
miR-374b CD46, CD55, F5, PAI-2 and TFPI
AT3: Anti-thrombin III. CD46: Cluster of differentiation 46. CD55: Cluster of differentiation 55. F5: Factor V.
F7: Factor VII. F8: Factor VIII. F11: Factor XI. F13: Factor XIII. PAI-1: Plasminogen activator inhibitor-1. PAI-
2: Plasminogen activator inhibitor-2. PLAT: tissue plasminogen activator. PLAU: urokinase-type
plasminogen activator. TF: Tissue factor. TFPI: Tissue factor pathway inhibitor.
doi:10.1371/journal.pone.0172131.t003
MicroRNAs regulating CD46 in cardioembolic and non-cardioembolic stroke
PLOS ONE | DOI:10.1371/journal.pone.0172131 February 15, 2017 12 / 16
Author Contributions
Conceptualization: KJ AA KST.
Formal analysis: JRT AA.
Funding acquisition: KJ PT-HW KST.
Investigation: JRT AA.
Methodology: KJ AA KST.
Resources: KST FLY CWW.
Validation: JRT AA.
Writing – original draft: JRT.
Writing – review & editing: KJ PT-HW AA.
References
1. Truelsen T, Begg S, Mathers C. The global burden of cerebrovascular disease. Global Burden of Dis-
eases 2006 update. World Health Organization. 2006. http://www.who.int/healthinfo/statistics/bod_
cerebrovasculardiseasestroke.pdf
2. Burke TA, Venketasubramanian RN. The epidemiology of stroke in the East Asian region: a literature-
based review. Int J Stroke. 2006; 1(4): 208–15. doi: 10.1111/j.1747-4949.2006.00060.x PMID:
18706018
3. Sudlow CL, Warlow CP. Comparable studies of the incidence of stroke and its pathological types:
results from an international collaboration. International Stroke Incidence Collaboration. Stroke. 1997;
28(3): 491–9. PMID: 9056601
4. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, et al. Classification of subtype
of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in
Acute Stroke Treatment. Stroke. 1993; 24(1): 35–41. PMID: 7678184
5. Farrell B, Godwin J, Richards S, Warlow C. The United Kingdom transient ischaemic attack (UK-TIA)
aspirin trial: final results. J Neurol Neurosurg Psychiatry. 1991; 54(12): 1044–54. PMID: 1783914
6. Jickling GC, Xu H, Stamova B, Ander BP, Zhan X, Tian Y, et al. Signatures of cardioembolic and large-
vessel ischemic stroke. Ann Neurol. 2010; 68(5): 681–92. doi: 10.1002/ana.22187 PMID: 21031583
7. Jickling GC, Stamova B, Ander BP, Zhan X, Liu D, Sison SM, et al. Prediction of cardioembolic, arterial,
and lacunar causes of cryptogenic stroke by gene expression and infarct location. Stroke. 2012; 43(8):
2036–41. doi: 10.1161/STROKEAHA.111.648725 PMID: 22627989
8. Liszewski MK, Farries TC, Lublin DM, Rooney IA, Atkinson JP. Control of the complement system. Adv
Immunol. 1996; 61: 201–83. PMID: 8834497
9. Song FY, Wu MH, Zhu LH, Zhang ZQ, Qi QD, Lou CL. Elevated Serum Mannose-Binding Lectin Levels
Are Associated with Poor Outcome After Acute Ischemic Stroke in Patients with Type 2 Diabetes. Mol
Neurobiol. 2015; 52(3): 1330–40. doi: 10.1007/s12035-014-8941-0 PMID: 25341475
10. Wang ZY, Sun ZR, Zhang LM. The relationship between serum mannose-binding lectin levels and
acute ischemic stroke risk. Neurochem Res. 2014; 39(2): 248–53. doi: 10.1007/s11064-013-1214-x
PMID: 24309995
11. Sze´plaki G, Szegedi R, Hirschberg K, Gombos T, Varga L, Kara´di I, et al. Strong complement activation
after acute ischemic stroke is associated with unfavorable outcomes. Atherosclerosis. 2009; 204(1):
315–20. doi: 10.1016/j.atherosclerosis.2008.07.044 PMID: 18804761
12. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with
antisense complementarity to lin-14. Cell. 1993; 75(5): 843–54. PMID: 8252621
13. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interfer-
ence by double-stranded RNA in Caenorhabditis elegans. Nature. 1998; 391(6669): 806–11. doi: 10.
1038/35888 PMID: 9486653
14. Sepramaniam S, Armugam A, Lim KY, Karolina DS, Swaminathan P, Tan JR, Jeyaseelan K. MicroRNA
320a functions as a novel endogenous modulator of aquaporins 1 and 4 as well as a potential therapeu-
tic target in cerebral ischemia. J Biol Chem. 2010; 285(38): 29223–30. doi: 10.1074/jbc.M110.144576
PMID: 20628061
MicroRNAs regulating CD46 in cardioembolic and non-cardioembolic stroke
PLOS ONE | DOI:10.1371/journal.pone.0172131 February 15, 2017 13 / 16
15. Kaur P, Tan JR, Karolina DS, Sepramaniam S, Armugam A, Wong PT, Jeyaseelan K. A long non-cod-
ing RNA, BC048612 and a microRNA, miR-203 coordinate the gene expression of neuronal growth reg-
ulator 1 (NEGR1) adhesion protein. Biochim Biophys Acta. 2016; 1863(4): 533–43. doi: 10.1016/j.
bbamcr.2015.12.012 PMID: 26723899
16. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Meth-
ods. 2012; 9(7): 671–5. PMID: 22930834
17. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that
thousands of human genes are microRNA targets. Cell. 2005; 120(1): 15–20. doi: 10.1016/j.cell.2004.
12.035 PMID: 15652477
18. Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of micro-
RNAs. Genome Res. 2009; 19(1): 92–105. doi: 10.1101/gr.082701.108 PMID: 18955434
19. Grimson A, Farh KK, Johnston WK, Garrett-Engele P, Lim LP, Bartel DP. MicroRNA targeting specificity
in mammals: determinants beyond seed pairing. Mol Cell. 2007; 27(1): 91–105. doi: 10.1016/j.molcel.
2007.06.017 PMID: 17612493
20. Garcia DM, Baek D, Shin C, Bell GW, Grimson A, Bartel DP. Weak seed-pairing stability and high tar-
get-site abundance decrease the proficiency of lsy-6 and other microRNAs. Nat Struct Mol Biol. 2011;
18(10): 1139–46. doi: 10.1038/nsmb.2115 PMID: 21909094
21. Betel D, Wilson M, Gabow A, Marks DS, Sander C. The microRNA.org resource: targets and expres-
sion. Nucleic Acids Res. 2008; 36(Database issue): D149–53. doi: 10.1093/nar/gkm995 PMID:
18158296
22. Betel D, Koppal A, Agius P, Sander C, Leslie C. Comprehensive modeling of microRNA targets predicts
functional non-conserved and non-canonical sites. Genome Biol. 2010; 11(8): R90. doi: 10.1186/gb-
2010-11-8-r90 PMID: 20799968
23. John B, Enright AJ, Aravin A, Tuschl T, Sander C, Marks DS. Human MicroRNA targets. PLoS Biol.
2004; 2(11): e363. doi: 10.1371/journal.pbio.0020363 PMID: 15502875
24. Enright AJ, John B, Gaul U, Tuschl T, Sander C, Marks DS. MicroRNA targets in Drosophila. Genome
Biol. 2003; 5(1): R1 doi: 10.1186/gb-2003-5-1-r1 PMID: 14709173
25. Griffiths-Jones S, Grocock RJ, van Dongen S, Bateman A, Enright AJ. miRBase: microRNA
sequences, targets and gene nomenclature. Nucleic Acids Res. 2006; 34(Database issue): D140–4.
doi: 10.1093/nar/gkj112 PMID: 16381832
26. Griffiths-Jones S, Saini HK, van Dongen S, Enright AJ. miRBase: tools for microRNA genomics. Nucleic
Acids Res. 2008; 36(Database issue): D154–8. doi: 10.1093/nar/gkm952 PMID: 17991681
27. Maragkakis M, Alexiou P, Papadopoulos GL, Reczko M, Dalamagas T, Giannopoulos G, et al. Accurate
microRNA target prediction correlates with protein repression levels. BMC Bioinformatics. 2009; 10:
295. doi: 10.1186/1471-2105-10-295 PMID: 19765283
28. Maragkakis M, Reczko M, Simossis VA, Alexiou P, Papadopoulos GL, Dalamagas T, et al. DIANA-
microT web server: elucidating microRNA functions through target prediction. Nucleic Acids Res. 2009;
37(Web Server issue): W273–6. doi: 10.1093/nar/gkp292 PMID: 19406924
29. Wang X, El Naqa IM. Prediction of both conserved and nonconserved microRNA targets in animals.
Bioinformatics. 2008; 24(3): 325–32. doi: 10.1093/bioinformatics/btm595 PMID: 18048393
30. Wang X. miRDB: a microRNA target prediction and functional annotation database with a wiki interface.
RNA. 2008; 14(6): 1012–7. doi: 10.1261/rna.965408 PMID: 18426918
31. Dweep H, Sticht C, Pandey P, Gretz N. miRWalk—database: prediction of possible miRNA binding
sites by "walking" the genes of three genomes. J Biomed Inform. 2011; 44(5): 839–47. doi: 10.1016/j.
jbi.2011.05.002 PMID: 21605702
32. Kertesz M, Iovino N, Unnerstall U, Gaul U, Segal E. The role of site accessibility in microRNA target rec-
ognition. Nat Genet. 2007; 39(10): 1278–84. doi: 10.1038/ng2135 PMID: 17893677
33. Elefant N, Berger A, Shein H, Hofree M, Margalit H, Altuvia Y. RepTar: a database of predicted cellular
targets of host and viral miRNAs. Nucleic Acids Res. 2011; 39(Database issue): D188–94. doi: 10.
1093/nar/gkq1233 PMID: 21149264
34. Yang JH, Li JH, Shao P, Zhou H, Chen YQ, Qu LH. starBase: a database for exploring microRNA-
mRNA interaction maps from Argonaute CLIP-Seq and Degradome-Seq data. Nucleic Acids Res.
2011; 39(Database issue): D202–9. doi: 10.1093/nar/gkq1056 PMID: 21037263
35. Li JH, Liu S, Zhou H, Qu LH, Yang JH. starBase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and
protein-RNA interaction networks from large-scale CLIP-Seq data. Nucleic Acids Res. 2014; 42(Data-
base issue): D92–7. doi: 10.1093/nar/gkt1248 PMID: 24297251
36. Miranda KC, Huynh T, Tay Y, Ang YS, Tam WL, Thomson AM, et al. A pattern-based method for the
identification of MicroRNA binding sites and their corresponding heteroduplexes. Cell. 2006; 126(6):
1203–17. doi: 10.1016/j.cell.2006.07.031 PMID: 16990141
MicroRNAs regulating CD46 in cardioembolic and non-cardioembolic stroke
PLOS ONE | DOI:10.1371/journal.pone.0172131 February 15, 2017 14 / 16
37. Vlachos IS, Kostoulas N, Vergoulis T, Georgakilas G, Reczko M, Maragkakis M, et al. DIANA miRPath
v.2.0: investigating the combinatorial effect of microRNAs in pathways. Nucleic Acids Res. 2012;
40(Web Server issue): W498–504. doi: 10.1093/nar/gks494 PMID: 22649059
38. Carmona-Saez P, Chagoyen M, Tirado F, Carazo JM, Pascual-Montano A. GENECODIS: a web-
based tool for finding significant concurrent annotations in gene lists. Genome Biol. 2007; 8(1): R3. doi:
10.1186/gb-2007-8-1-r3 PMID: 17204154
39. Nogales-Cadenas R, Carmona-Saez P, Vazquez M, Vicente C, Yang X, Tirado F, et al. GeneCodis:
interpreting gene lists through enrichment analysis and integration of diverse biological information.
Nucleic Acids Res. 2009; 37(Web Server issue): W317–22. doi: 10.1093/nar/gkp416 PMID: 19465387
40. Tabas-Madrid D, Nogales-Cadenas R, Pascual-Montano A. GeneCodis3: a non-redundant and modu-
lar enrichment analysis tool for functional genomics. Nucleic Acids Res. 2012; 40(Web Server issue):
W478–83. doi: 10.1093/nar/gks402 PMID: 22573175
41. Saeed AI, Sharov V, White J, Li J, Liang W, Bhagabati N, et al. TM4: a free, open-source system for
microarray data management and analysis. Biotechniques. 2003; 34(2): 374–8. PMID: 12613259
42. Sepramaniam S, Tan JR, Tan KS, DeSilva DA, Tavintharan S, Woon FP, et al. Circulating microRNAs
as biomarkers of acute stroke. Int J Mol Sci. 2014; 15(1): 1418–32. doi: 10.3390/ijms15011418 PMID:
24447930
43. Dejana E. The role of wnt signaling in physiological and pathological angiogenesis. Circ Res. 2010; 107
(8): 943–52. doi: 10.1161/CIRCRESAHA.110.223750 PMID: 20947863
44. Walshe TE, Saint-Geniez M, Maharaj AS, Sekiyama E, Maldonado AE, D’Amore PA. TGF-beta is
required for vascular barrier function, endothelial survival and homeostasis of the adult microvascula-
ture. PLoS One. 2009; 4(4): e5149. doi: 10.1371/journal.pone.0005149 PMID: 19340291
45. Wallez Y, Huber P. Endothelial adherens and tight junctions in vascular homeostasis, inflammation and
angiogenesis. Biochim Biophys Acta. 2008; 1778(3): 794–809. doi: 10.1016/j.bbamem.2007.09.003
PMID: 17961505
46. Hansson GK, Robertson AK, So¨derberg-Naucle´r C. Inflammation and atherosclerosis. Annu Rev
Pathol. 2006; 1: 297–329. doi: 10.1146/annurev.pathol.1.110304.100100 PMID: 18039117
47. Seifert PS, Hansson GK. Complement receptors and regulatory proteins in human atherosclerotic
lesions. Arteriosclerosis. 1989; 9(6): 802–11. PMID: 2480105
48. Li SH, Szmitko PE, Weisel RD, Wang CH, Fedak PW, Li RK, et al. C-reactive protein upregulates com-
plement-inhibitory factors in endothelial cells. Circulation. 2004; 109(7): 833–6. doi: 10.1161/01.CIR.
0000117087.27524.0E PMID: 14967730
49. Liu CZ, Liu W, Zheng Y, Su JM, Li JJ, Yu L, He XD, Chen SS. PTEN and PDCD4 are bona fide targets
of microRNA-21 in human cholangiocarcinoma. Chin Med Sci J. 2012; 27(2): 65–72. PMID: 22770403
50. Bohmer M, Sharbati J, Zur Bruegge J, Einspanier R, Sharbati S. Structural analysis of microRNA-target
interaction by sequential seed mutagenesis and stem-loop 3’ RACE. PLoS One. 2013; 8(11): e81427.
doi: 10.1371/journal.pone.0081427 PMID: 24282594
51. Jiang WL, Zhang YF, Xia QQ, Zhu J, Yu X, Fan T, et al. MicroRNA-19a regulates lipopolysaccharide-
induced endothelial cell apoptosis through modulation of apoptosis signal-regulating kinase 1 expres-
sion. BMC Mol Biol. 2015; 16: 11. doi: 10.1186/s12867-015-0034-8 PMID: 25982447
52. Wang X, Lin WH, Zhao YD, Chen XY, Leung TW, Chen C,et al. The effectiveness of dual antiplatelet
treatment in acute ischemic stroke patients with intracranial arterial stenosis: a subgroup analysis of
CLAIR study. Int J Stroke. 2013; 8(8): 663–8. doi: 10.1111/j.1747-4949.2012.00828.x PMID: 22883712
53. Hallevi H, Albright KC, Martin-Schild S, Barreto AD, Savitz SI, Escobar MA, et al. Anticoagulation after
cardioembolic stroke: to bridge or not to bridge? Arch Neurol. 2008; 65(9): 1169–73. doi: 10.1001/
archneur.65.9.noc70105 PMID: 18625852
54. Jickling GC, Ander BP, Zhan X, Noblett D, Stamova B, Liu D. microRNA expression in peripheral blood
cells following acute ischemic stroke and their predicted gene targets. PLoS One. 2014; 9(6): e99283.
doi: 10.1371/journal.pone.0099283 PMID: 24911610
55. De Martino I, Visone R, Fedele M, Petrocca F, Palmieri D, Martinez Hoyos J, Forzati F, Croce CM,
Fusco A. Regulation of microRNA expression by HMGA1 proteins. Oncogene. 2009; 28(11):1432–42.
doi: 10.1038/onc.2008.495 PMID: 19169275
56. Wayman GA, Davare M, Ando H, Fortin D, Varlamova O, Cheng HY, Marks D, Obrietan K, Soderling
TR, Goodman RH, Impey S. An activity-regulated microRNA controls dendritic plasticity by down-regu-
lating p250GAP. Proc Natl Acad Sci U S A. 2008; 105(26): 9093–8. doi: 10.1073/pnas.0803072105
PMID: 18577589
57. Place RF, Li LC, Pookot D, Noonan EJ, Dahiya R. MicroRNA-373 induces expression of genes with
complementary promoter sequences. Proc Natl Acad Sci U S A. 2008; 105(5): 1608–13. doi: 10.1073/
pnas.0707594105 PMID: 18227514
MicroRNAs regulating CD46 in cardioembolic and non-cardioembolic stroke
PLOS ONE | DOI:10.1371/journal.pone.0172131 February 15, 2017 15 / 16
58. Kim DH, Saetrom P, Snøve O Jr, Rossi JJ. MicroRNA-directed transcriptional gene silencing in mam-
malian cells. Proc Natl Acad Sci U S A. 2008; 105(42): 16230–5. doi: 10.1073/pnas.0808830105
PMID: 18852463
59. Baglı`o SR, Devescovi V, Granchi D, Baldini N. MicroRNA expression profiling of human bone marrow
mesenchymal stem cells during osteogenic differentiation reveals Osterix regulation by miR-31. Gene.
2013; 527(1): 321–31. doi: 10.1016/j.gene.2013.06.021 PMID: 23827457
MicroRNAs regulating CD46 in cardioembolic and non-cardioembolic stroke
PLOS ONE | DOI:10.1371/journal.pone.0172131 February 15, 2017 16 / 16
